Search results
Results from the WOW.Com Content Network
Some drug-induced cases While the primary symptom of Cyanopsia is a blue tint to vision, the exact reasons why some individuals experience this phenomenon while others do not, remain unclear. Variations in retinal sensitivity, individual responses to medications, or differences in post-surgical adaptation may contribute.
Illusory palinopsia is often worse with high stimulus intensity and contrast ratio in a dark adapted state.Multiple types of illusory palinopsia often co-exist in a patient and occur with other diffuse, persistent illusory symptoms such as halos around objects, dysmetropsia (micropsia, macropsia, pelopsia, or teleopsia), Alice in Wonderland Syndrome, visual snow, and oscillopsia.
Palinopsia (Greek: palin for "again" and opsia for "seeing") is the persistent recurrence of a visual image after the stimulus has been removed. [1] Palinopsia is not a diagnosis; it is a diverse group of pathological visual symptoms with a wide variety of causes.
The injectable drug, which is sold under the brand names Wegovy and Ozempic, is FDA-approved to help with weight loss and type 2 diabetes, but research and general use by the public has turned up ...
Oculogyric crisis (OGC) is a rare sudden, paroxysmal, dystonic reaction that may manifest in response to specific drugs, particularly neuroleptics, or medical conditions, such as movement disorders. This neurological phenomenon is characterized by a sustained dystonic, conjugate, involuntary upward deviation of both eyes lasting seconds to hours.
The most prevalent research on prescription drugs with side effects of macropsia deals with zolpidem and citalopram. Zolpidem is a drug prescribed for insomnia, and although it has proven beneficial effects, there have been numerous reported cases of adverse perceptual reactions. [ 13 ]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Several changes are coming to Medicare Part D prescription drug plans in 2025 that could impact drug costs and plan coverage. One change is an annual $2,000 out-of-pocket cap.